Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2023 | 3 |
2024 | 2 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
J Clin Invest. 2023 Nov 15;133(22):e170169. doi: 10.1172/JCI170169.
J Clin Invest. 2023.
PMID: 37751299
Free PMC article.
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS.
Herbaux C, et al. Among authors: collins mc.
Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303.
Blood. 2021.
PMID: 33598678
Free article.
Clinical Trial.
Item in Clipboard
Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
Zhu F, Crombie JL, Ni W, Hoang NM, Garg S, Hackett L, Chong SJF, Collins MC, Rui L, Griffin J, Davids MS.
Zhu F, et al. Among authors: collins mc.
Haematologica. 2024 Jan 1;109(1):186-199. doi: 10.3324/haematol.2023.283245.
Haematologica. 2024.
PMID: 37534528
Free PMC article.
Item in Clipboard
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS.
Ryan CE, et al. Among authors: collins mc.
Leukemia. 2023 Apr;37(4):835-842. doi: 10.1038/s41375-023-01830-2. Epub 2023 Jan 30.
Leukemia. 2023.
PMID: 36717653
Clinical Trial.
Item in Clipboard
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y.
Ailawadhi S, et al. Among authors: collins mc.
Clin Cancer Res. 2023 Jul 5;29(13):2385-2393. doi: 10.1158/1078-0432.CCR-22-3321.
Clin Cancer Res. 2023.
PMID: 37074726
Free PMC article.
Item in Clipboard
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
Lakhani NJ, Rasco D, Wang H, Men L, Liang E, Fu T, Collins MC, Min P, Yin Y, Davids MS, Yang D, Zhai Y.
Lakhani NJ, et al. Among authors: collins mc.
Clin Cancer Res. 2024 Feb 1;30(3):506-521. doi: 10.1158/1078-0432.CCR-23-1525.
Clin Cancer Res. 2024.
PMID: 37971712
Item in Clipboard
Cite
Cite